Clinical trial · Observational
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
Assessing the Expression of A2R Receptors and CD39 and CD73 Ectonucleotidases on Circulating Tumour Cells of Non-small Cell Lung Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no patients enrolled
Summary
Brief summary (as posted)
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- NSCLC patients
- description
- Patients with proven stage IA-IIB non-small cell lung cancer (NSCLC).
- interventionNames
- Biological: Sample
Primary outcomes (1)
- measure
- Ex vivo expression of A2R (adenosine receptor), CD39, CD73 and P2RX7 on NSCLC and CTC
- timeFrame
- At inclusion
- description
- Presence versus Absence of expression (immunohistochemistry)
Secondary outcomes (1)
- measure
- In vitro impact of radiation therapy on the A2R, CD39, CD73 expression by cells lineage
- timeFrame
- At inclusion
- description
- Upregulation / Downregulation of expression (mRNA by real time PCR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
i) Inclusion criteria: * Patient of legal age (\>18 years), any gender, * operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC) ii) Exclusion criteria: * Patient with any other active cancer. * Lack of evaluable material.
References
Publications (0)
Data not yet available